The new drug is already well on its way to the market, but it could be months before it reaches consumers.
The new formulation of the Malaria Drugs Development Corporation’s malaria vaccine is already in phase 3 trials and is expected to be ready for use in 2021.
The vaccine is based on a combination of a human version of the vaccine and a modified variant that contains a gene from the parasite that infects humans.
It’s also designed to target a specific genetic mutation in a certain strain of the parasite.
The company is now in the middle of a second phase 3 trial to assess whether the vaccine can be used in people who are already infected with the virus.
The new formulation is also expected to have a wider spectrum of efficacy, as it is also targeting a particular genetic mutation that occurs in about 1 in every 200 infected people.
The gene in the vaccine is the same as one that causes the disease in people with the parasite, but this is not a factor that is seen in people without the disease.
According to a Reuters analysis of clinical trials that have taken place, this is the first time the Malay-language version of this vaccine has been approved.
However, the new vaccine will be used for both men and women.
The drug’s price is expected, at about $2,500 per month.
The drug is not available in the US and other countries where it is approved.
The company is also in the midst of a trial to test the efficacy of a more powerful version of its vaccine, called Malaria Titer.
The test, which is scheduled to be completed in 2021, is designed to determine whether the efficacy is more than a placebo, which would be an indication that the drug is effective in reducing malaria deaths.
The Malaria Drug Development Corporation has also been working on a new malaria vaccine for women.
The vaccine is expected in 2021 for women ages 15 to 39.
The trial is intended to test whether the women are more vulnerable to malaria and have more difficulty controlling their infection, a condition that can lead to an increased risk of malaria transmission.
The companies’ trials for the malaria vaccine are currently underway.
Malaria is the most common cause of death among children and young adults in the developing world, and there is an estimated 20 million deaths annually from malaria in the region.
The disease kills an estimated 2.2 million people every year.
The United Nations estimates that 1.5 million children are infected with malaria each year, and an estimated 1.1 million die.